Acceleron Announces Proposed Public Offering of Common Stock
14 Enero 2019 - 3:04PM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta superfamily
therapeutics to treat serious and rare hematologic, neuromuscular,
and pulmonary diseases, today announced that it intends to offer
and sell, subject to market and other conditions, $200 million of
its common stock in an underwritten public offering. As part of
this offering, Acceleron intends to grant the underwriters a 30-day
option to purchase up to an additional fifteen percent (15%) of the
shares of common stock offered in the public offering. All of the
shares in the proposed offering are to be sold by Acceleron.
Citigroup, J.P. Morgan and SVB Leerink are acting as joint
book-running managers for the offering.
Acceleron intends to use the net proceeds from the offering to
conduct clinical trials and associated activities with therapeutic
candidates from its existing research pipeline and for general and
administrative expenses (including personnel-related costs),
potential future development programs, capital expenditures and
working capital and other general corporate purposes, including
potential acquisitions of rights to additional programs from third
parties. The securities described above are being offered by
Acceleron pursuant to its registration statement on Form S-3 filed
with the Securities and Exchange Commission (the “SEC”) on
September 19, 2017, which became effective automatically when it
was filed. The offering will be made only by means of a preliminary
prospectus supplement and accompanying prospectus, copies of which
may be obtained, when available, from Citigroup Global Markets
Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 or telephone: 1-800-831-9146; J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204
or email: prospectus-eq_fi@jpmchase.com; and SVB Leerink LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA, 02110, by e-mail at syndicate@leerink.com, or by phone
at 800-808-7525, ext. 6132. The final terms of the offering will be
disclosed in a final prospectus supplement to be filed with the
SEC.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities in the offering, nor
shall there be any sale of these securities in any jurisdiction in
which an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
jurisdiction.
About Acceleron
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical
company dedicated to the discovery, development, and
commercialization of therapeutics to treat serious and rare
diseases. The Company's leadership in the understanding of TGF-beta
biology and protein engineering generates innovative compounds that
engage the body's ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2
pulmonary program with sotatercept in pulmonary arterial
hypertension.
Cautionary Note on Forward-Looking Statements
Certain statements contained in this release, including those
relating to the use of proceeds from the sale of common stock, are
forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. These risks and
uncertainties include, but are not limited to, risks and
uncertainties associated with the consummation of the proposed
offering and general economic conditions and other risks identified
from time to time in the reports we file with the SEC, including
our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K, which are available at www.sec.gov. We
caution investors not to place considerable reliance on the
forward-looking statements contained in this press release. The
forward-looking statements in this press release speak only as of
the date of this document, and we undertake no obligation to update
or revise any of the statements. Our business is subject to
substantial risks and uncertainties, including those referenced
above. Investors, potential investors, and others should give
careful consideration to these risks and uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190114005791/en/
Investors:Acceleron PharmaTodd James, IRC, (617) 649-9393Vice
President, Investor Relations and Corporate Communications
Media:Matt Fearer, (617) 301-9557Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024